CVS Agrees to $315 Million Federal Opioid Settlement

Marcus Bell · 2026-10-13T21:20:23.841Z

CVS should face real penalties beyond a fine if they were filling questionable opioid scripts that fueled the crisis.

CVS Agrees to $315 Million Federal Opioid Settlement — Photo: John Phelan / Wikimedia Commons (CC BY 4.0)

Sponsored

$315 million. That's what CVS will pay. On October 13, 2026, the Justice Department said CVS will settle allegations that from October 17, 2013 through December 2, 2025 it filled invalid or medically unjustified opioid prescriptions and billed federal health programs. A December 2024 Rhode Island suit under the False Claims Act by former employee Hillary Estright alleged excessive quantities, early refills, trinity prescriptions, and pill-mill fills despite red flags. Associate Attorney General Stanley E. Woodward Jr. called it a milestone that holds bad actors accountable. Assistant Attorney General Brett Shumate said CVS must add safeguards so controlled substances are dispensed only when medically appropriate. He said proactive monitoring will protect patients and federal programs. CVS said it cooperated more than four years and strongly disagrees with the allegations and false narrative. It said the lawsuit intensifies a dilemma for pharmacists second-guessed for dispensing too many or too few opioids. CVS denies wrongdoing; the settlement admits no liability. A DEA memorandum requires a Controlled Substance Dispensing Oversight Program, a reporting hotline, and monitoring of dispensing patterns. Walgreens paid $350 million in April 2025 on similar claims; Walmart paid $50 million in August. Omnicare, a CVS subsidiary, took a $949 million judgment in 2025; its sale was approved in May.